Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 1997 Feb 1;89(3):739-61.

Iron-chelating therapy and the treatment of thalassemia.

Author information

1
Hospital for Sick Children, Toronto, Ontario, Canada.

Erratum in

  • Blood 1997 Apr 1;89(7):2621.

Abstract

Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically altered the prognosis of this previously fatal disease. The successes achieved with deferoxamine, as well as the limitations of this treatment, have stimulated the design of alternative strategies of iron-chelating therapy, including orally active iron chelators. The development of the most promising of these, deferiprone, has progressed rapidly over the last 5 years; data from several trials have provided direct and supportive evidence for its short-term efficacy. At the same time, the toxicity of this agent mandates a careful evaluation of the balance between risk and benefit of deferiprone in patients with thalassemia, in most of whom long-term deferoxamine is safe and efficacious therapy.

PMID:
9028304
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center